Miltenyi Biotec India Pvt. Ltd. and the Biotechnology Industry Research Assistance Council (BIRAC) have entered into a strategic Letter of Intent (LoI). The collaboration, formalised during the ongoing BIO International Convention 2025 in Boston, reflects a shared vision to enhance indigenous capabilities in next-generation therapeutics.

The agreement outlines a multifaceted roadmap to advance India’s CGT capabilities, ranging from workforce training and translational research to point-of-care (PoC) CAR-T manufacturing and startup mentorship. This partnership is expected to play a pivotal role in transforming India into a global centre of excellence in advanced therapies.

As part of the ceremonial occasion, Miltenyi Biotec India had the distinction of inaugurating the India Pavilion alongside senior dignitaries from BIRAC and the Department of Biotechnology (DBT). The ribbon-cutting ceremony symbolised India’s growing influence in the global biotech innovation space.

The core pillars of the collaboration include:

• Capacity Building: Launching comprehensive training programs to upskill clinicians, scientists, and technicians in CGT manufacturing, analytics, and quality control.
• Research Collaboration: Driving academic and multi-centre clinical studies that address pressing medical needs, especially in the fields of oncology, autoimmune disorders, and rare diseases.
• Localised Manufacturing: Establishing PoC CAR-T centres across the country using Miltenyi’s CliniMACS Prodigy system, a move aimed at making cell therapies more accessible and cost-effective.
• Startup Ecosystem Support: Encouraging innovation by identifying and nurturing Indian biotech startups, aligned with the ‘Make in India’ initiative, and enabling local production of critical components.

Commenting on the development, Priya Kapoor-Hingorani, Managing Director of Miltenyi Biotec India, said, “The potential of India draws us. Our partnership with BIRAC focuses on updating and upskilling scientists to strengthen the country’s scientific capabilities and infrastructure. Together, we’re exploring how to address current unmet needs in medical science, particularly in areas like autoimmune and rare diseases by enhancing access through innovative mechanisms such as point-of-care CAR-T and graft engineering.”

Dr. Jitendra Kumar, Managing Director, BIRAC, also emphasised the strategic significance of the collaboration, stating, “The government is signing this Letter of Intent with a multinational company renowned for its expertise in cell and gene therapy. India aspires to become a global leader in this space, and achieving that goal requires a strong foundation of skilled manpower. Miltenyi has committed to supporting this vision by contributing to training and capacity building.”

Also read: ICICI Bank & TMC Launch Advanced Cancer Care Block in Andhra Pradesh with ₹550 Crore Investment

The initiative underscores a transformative moment for India’s CGT ecosystem, merging global technological know-how with public sector commitment. This partnership aims to accelerate access to innovative treatments for patients while also positioning India as a biotechnology innovation hub.

Like

Dislike

Be a part of Elets Collaborative Initiatives. Join Us for Upcoming Events and explore business opportunities. Like us on Facebook , connect with us on LinkedIn and follow us on Twitter , Instagram.

"Exciting news! Elets technomedia is now on WhatsApp Channels Subscribe today by clicking the link and stay updated with the latest insights!" Click here!